Mercado mundial de terapia fotodinámica contra el cáncer: tendencias de la industria y pronóstico hasta 2031

Análisis y tamaño del mercado de la terapia fotodinámica contra el cáncer

La terapia fotodinámica (TFD) contra el cáncer tiene una naturaleza no invasiva, que la distingue de los tratamientos tradicionales contra el cáncer, como la cirugía, la quimioterapia o la radioterapia. La TFD implica la administración de un agente fotosensibilizador, que se acumula selectivamente en las células cancerosas. Su enfoque dirigido minimiza la necesidad de procedimientos invasivos, reduce el riesgo de complicaciones y mejora la comodidad y la recuperación del paciente, lo que hace que la TFD sea una opción atractiva para los pacientes que buscan tratamientos contra el cáncer menos invasivos.

El tamaño del mercado mundial de terapia fotodinámica contra el cáncer se valoró en USD 3.76 mil millones en 2023 y se proyecta que alcance los USD 5.25 mil millones para 2031, con una CAGR del 4.25% durante el período de pronóstico de 2024 a 2031. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance del informe y segmentación del mercado       

Market Definition

Cancer photodynamic therapy (PDT) is a treatment that uses a photosensitizing agent and light to target and destroy cancer cells. The photosensitizer is activated by specific wavelengths of light, generating reactive oxygen species that kill the cancer cells while minimizing damage to surrounding healthy tissue.

Cancer Photodynamic Therapy Market Dynamics

Drivers                                                                                          

• High Demand for Cancer Photodynamic Therapy due to Increased Incidence of Cancer

With cancer rates on the ascent, there is an escalating demand for effective and less invasive treatment options such as PDT. This demand is particularly pronounced as patients seek therapies with reduced side effects and improved outcomes. PDT's minimally invasive nature and potential for outpatient treatment make it an attractive option amidst the increasing burden of cancer. Consequently, the growing prevalence of cancer fuels both the adoption of PDT by healthcare providers and investment in PDT research and development by pharmaceutical companies, contributing to market expansion.

• Increased Technological Advancements Enhances Cancer Photodynamic Therapy

Technological advancements encompass improvements in light sources, photosensitizers, and delivery systems, enhancing treatment efficacy and safety. Innovations such as targeted PDT, using specific molecules to selectively target cancer cells, are reducing off-target effects and improving outcomes. Additionally, advancements in imaging technologies enable better localization of tumors, optimizing PDT precision. Integration with other treatment modalities, such as immunotherapy and targeted therapy, further enhances therapeutic efficacy, making PDT a promising option in the oncology landscape.

Opportunities

• Expansion of Cancer Photodynamic Therapy Due to Personalized Approaches

PDT's ability to selectively target cancer cells while sparing healthy tissue aligns with the principles of personalized medicine, ensuring precise and targeted therapy. This customized approach enhances treatment efficacy, minimizes side effects, and improves patient outcomes, driving the integration of PDT into personalized cancer care paradigms. As research continues to uncover biomarkers and therapeutic targets, PDT's adaptability and precision will further propel its adoption as a personalized cancer treatment modality.

• Impact of Regulatory Environment on Adoption of Cancer Photodynamic Therapy

Regulatory agencies such as the FDA and EMA evaluate the safety and efficacy of PDT technologies and indications, providing guidelines for market approval and usage. Compliance with regulatory requirements is essential for market entry and commercialization of PDT products. Clear regulatory pathways facilitate innovation and market growth by providing companies with a framework for development and commercialization. Changes in regulations, such as expanded indications or streamlined approval processes, can significantly impact market dynamics and investment decisions within the cancer PDT market. Therefore, staying abreast of regulatory updates is essential for market participants to navigate effectively.

Restraints/Challenges

• High Development Costs Limit the Adoption of Cancer Photodynamic Therapy

PDT requires substantial investment in research and development to advance photosensitizer compounds, light sources, and delivery systems. These costs include preclinical studies, clinical trials, and regulatory approvals, contributing to the overall expense of bringing PDT products to market. These high development costs may discourage investment from smaller companies and limit the number of players entering the market, potentially slowing down innovation and market growth in the long term.

• High Complexity limits the Demand for Cancer Photodynamic Therapy

PDT requires specialized equipment, trained personnel, and specific protocols for effective administration. This complexity can limit the availability of PDT in healthcare settings, particularly in resource-constrained regions or facilities lacking the necessary infrastructure. The need for precise light delivery and photosensitizer activation further adds to the technical challenges of PDT. As a result, the widespread implementation of PDT may be hindered, impacting its uptake and market penetration compared to more accessible treatment modalities.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In August 2022, Asieris Pharmaceuticals reached a milestone as its multinational Phase III Clinical Trial of Cevira (APRICITY) concluded enrollment. Cevira represents a novel non-surgical approach to treating cervical high-grade squamous intraepithelial lesions (HSIL). This breakthrough therapy combines a photosensitizer that accumulates in target cells with a drug-device combination product, promising significant advancements in cervical lesion management
• In March 2022, Biofrontera Inc. achieved a significant regulatory milestone with the inclusion of the previously granted U.S. patent No. 11,235,169 for the BF-RhodoLED XL illumination device in the U.S. Food and Drug Administration (FDA) publication 'Approved Drug Products with Therapeutic Equivalence Evaluations,' commonly referred to as the Orange Book. This recognition underscores the device's importance and paves the way for its widespread utilization in photodynamic therapy applications

Cancer Photodynamic Therapy Market Scope

The market is segmented on the basis of multiple cancer treatments, product, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them in making strategic decisions for the identification of core market applications.

Multiple Cancer Treatments

• Non-Melanoma Skin Cancer
• Prostate Cancer
• Breast Cancer
• Brain Tumor
• Lung Cancer
• Head and Neck Cancer
• Oral Lesions
• Oesophageal Cancer
• Cervical Cancer
• Colorectal Cancer
• Cancer of the Bile Duct the Pancreas

Product

• Photosensitizer Drug
• Photodynamic Therapy Devices

End User

• Hospitals
• Cancer Treatment Centers
• Others

Cancer Photodynamic Therapy Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by multiple cancer treatments, product and end user as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina and rest of South America.

North America dominance in the market is attributed to its advanced healthcare infrastructure, facilitating better access to cutting-edge treatments. Additionally, the region's significant investments in research and development enhance the innovation and efficacy of photodynamic therapy techniques, fostering market growth. These factors position North America to lead in advancements and adoption of cancer photodynamic therapy, driving expansion throughout the forecast period.

Asia-Pacific is expected to substantially expand in the cancer photodynamic therapy market, which is primarily driven by a growing healthcare infrastructure. Government initiatives are expected to play a pivotal role in accelerating this growth trajectory and fostering advancements in cancer treatment technologies. As healthcare access improves and awareness increases, the region stands to witness a notable surge in demand for photodynamic therapy solutions, positioning it as a key growth market in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Cancer Photodynamic Therapy Market Analysis

El panorama competitivo del mercado proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y variedad de productos, y el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado.

Algunos de los principales actores que operan en el mercado son:

• Theralase Technologies Inc. (Canadá)
• Biofrontera AG (Alemania)
• Hologic, Inc. (Estados Unidos)
• Bausch + Lomb.(Canadá)
• Quest PharmaTech Inc. (Canadá)
• LUMIBIRD (Francia)
• Galderma SA (Suiza)
• Modulight, Inc. (Estados Unidos)
• Industrias farmacéuticas Sun Ltd. (India)
• SUS Advancing Technology Co., Ltd. (Japón)
• Novartis AG (Suiza)
• Allergan Plc (Irlanda)
• Valeant Pharmaceuticals International (Canadá)
• Laboratorios Dr. Reddy Ltd (India)
• Laboratorios Bedford (Estados Unidos)
• Fresenius Kabi AG (Alemania)
• Zydus Pharmaceuticals, Inc. (India)
• Grupo farmacéutico Mayne Limited (Australia)
• Productos farmacéuticos Glenmark (India)

SKU-66189